Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis

NCT01438463 is registered in ClinicalTrials.gov with HAL Allergy as lead sponsor.

NCT NCT01438463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01438463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis
Lead sponsor
HAL Allergy
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
May 31, 2013
Enrollment
290 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, allergic rhinoconjunctivitis